Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.

ABSTRACT:

Importance

Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study. However, the full extent of mavacamten's effects on exercise performance remains unclear.

Objective

To investigate the effect of mavacamten on exercise physiology using cardiopulmonary exercise testing (CPET).

Design, setting, and participants

Exploratory analyses of the data from the EXPLORER-HCM study, a randomized, double-blind, placebo-controlled, phase 3 trial that was conducted in 68 cardiovascular centers in 13 countries. In total, 251 patients with symptomatic obstructive HCM were enrolled.

Interventions

Patients were randomly assigned in a 1:1 ratio to mavacamten or p

SUBMITTER: Wheeler MT 

PROVIDER: S-EPMC9857843 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature